You are using an unsupported version of . Some features may not work correctly. Please install the latest version of .
Orphan Drugs and Rare Diseases
As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs.
No content found.
There seems to have been an error, please try again.